Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

por Rugo, Hope S., Pennella, Eduardo J., Gopalakrishnan, Unmesh, Hernandez-Bronchud, Miguel, Herson, Jay, Koch, Hans Friedrich, Loganathan, Subramanian, Deodhar, Sarika, Marwah, Ashwani, Manikhas, Alexey, Bondarenko, Igor, Parra, Joseph D., Abesamis-Tiambeng, Maria Luisa T., Akewanlop, Charuwan, Vynnychenko, Ihor, Sriuranpong, Virote, Roy, Sirshendu, Yanez Ruiz, Eduardo Patricio, Barve, Abhijit, Waller, Cornelius F.
Publicado 2021

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

por Rugo, Hope S., Pennella, Eduardo J., Gopalakrishnan, Unmesh, Hernandez-Bronchud, Miguel, Herson, Jay, Koch, Hans Friedrich, Loganathan, Subramanian, Deodhar, Sarika, Marwah, Ashwani, Manikhas, Alexey, Bondarenko, Igor, Mukhametshina, Guzel, Nemsadze, Gia, Parra, Joseph D., Abesamis-Tiambeng, Maria Luisa T., Baramidze, Kakhaber, Akewanlop, Charuwan, Vynnychenko, Ihor, Sriuranpong, Virote, Mamillapalli, Gopichand, Roy, Sirshendu, Yanez Ruiz, Eduardo Patricio, Barve, Abhijit, Fuentes-Alburo, Adolfo, Waller, Cornelius F.
Publicado 2021